INSMED Inc — Director's Dealing 2021

Jan 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INSMED Inc (INSM)
CIK: 0001104506
Period of Report: 2021-01-25

Reporting Person: Pellizzari Christine A (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-25	Common Stock	M	15000	$10.85	Acquired	155721	Direct
2021-01-25	Common Stock	S	15000	$42.95	Disposed	140721	Direct
2021-01-25	Common Stock	M	6000	$10.85	Acquired	146721	Direct
2021-01-25	Common Stock	S	6000	$43.84	Disposed	140721	Direct
2021-01-26	Common Stock	M	2600	$10.85	Acquired	143321	Direct
2021-01-26	Common Stock	S	2600	$44.04	Disposed	140721	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-25	Stock Option (right to buy)	$10.85	M	15000	Disposed	2026-05-19	Common Stock (15000)	Direct
2021-01-25	Stock Option (right to buy)	$10.85	M	6000	Disposed	2026-05-19	Common Stock (6000)	Direct
2021-01-26	Stock Option (right to buy)	$10.85	M	2600	Disposed	2026-05-19	Common Stock (2600)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: This is the weighted average sales price representing 15,000 shares sold at prices ranging from $42.75 to $43.58 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F3: This is the weighted average sales price representing 6,000 shares sold at prices ranging from $43.75 to $43.94 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F4: This is the weighted average sales price representing 2,600 shares sold at prices ranging from $43.75 to $44.23 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request

F5: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant.